About this item:

534 Views | 370 Downloads

Author Notes:

Correspondence to: Lawrence S. Phillips, M.D., Atlanta VA Medical Center, 1670 Clairmont Road, Room 11C-110A, Decatur, GA 30033, p 404-728-7608, f 404-727-1300, medlsp@emory.edu.

YY and LP researched the data, QL performed the statistical analyses, YY drafted the manuscript, and LP, AT, SJ, DO, MR, and all of the other authors contributed to the discussion and reviewed/edited the manuscript.

The authors gratefully acknowledge the contributions of Christine Jasien, Atlanta VAMC who assisted the authors with obtaining VINCI data.

We also acknowledge Qing He, Emory School of Public Health, for assistance with data analysis.

With regard to potential conflicts of interest, within the past five years, Dr. Phillips has served on Scientific Advisory Boards for Boehringer Ingelheim, Profil and Janssen, and has or had research support from Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Glaxo SmithKline, Janssen, Vascular Pharmaceuticals, Glaxo SmithKline, Astra Zeneca, and the Cystic Fibrosis Foundation. In the past, he was a speaker for Novartis and Merck, but not for the last five years.

Darin E Olson has research support from Novo Nordisk and Amylin, and Qi Long receives support from NIH, PCORI, NSF, AHA, and the Cystic Fibrosis Foundation and served as a consultant for Eisai.

Sandra Jackson received support from Amylin.

After the study reported here was completed, Dr. Phillips founded a company, Diasyst Inc., which aims to develop and commercialize diabetes management programs.

Other authors have no potential conflicts of interest to declare.

Subjects:

Research Funding:

This work was supported in part by FDA award RO1FD003527 (L.S.P), VA awards HSR&D IIR 07-138 (L.S.P, S.L.J.), and I01-CX001025 and I01-01BX003340 (L.S.P.), NIH awards R21DK099716 (L.S.P., Q.L., and S.L.J.), DK066204 (L.S.P.), U01 DK091958 (L.S.P. and M.K.R.), U01 DK098246 (L.S.P. and D.E.O.), R21 NS091630 (Q.L.), and a Cystic Fibrosis Foundation award PHILLI12A0 (L.S.P).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Medicine, General & Internal
  • General & Internal Medicine
  • Diabetes
  • Midlevel providers
  • Nurse practitioner
  • Physician assistant
  • Primary care
  • PRIMARY-CARE
  • PROVIDERS
  • MELLITUS
  • OUTCOMES
  • INSULIN
  • QUALITY
  • VA

Nurse Practitioners, Physician Assistants, and Physicians Are Comparable in Managing the First Five Years of Diabetes

Tools:

Journal Title:

American Journal of Medicine

Volume:

Volume 131, Number 3

Publisher:

, Pages 276-+

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: Increasing use of nurse practitioners and physician assistants is a possible solution to the shortage of primary care providers in the United States, but the quality of care they provide is not well understood. Methods: Because the scope of practice of the 3 provider types is similar in the Veterans Health Administration, we determined whether patients managed by primary care nurse practitioners, physician assistants, or physicians had similar hemoglobin A1c levels at comparable times in the natural history of diabetes. Our retrospective cohort study examined veterans with newly diagnosed diabetes in 2008, continuous primary care from 2008 to 2012, and more than 75% of primary care visits with nurse practitioner, physician assistant, or physician. Results: Of the 19,238 patients, 95.3% were male, 77.7% were white, and they had a mean age 68.5 years; 14.7%, 7.1%, and 78.2% of patients were managed by nurse practitioners, physician assistants, and physicians, respectively. Median hemoglobin A1c was comparable at diagnosis (6.6%, 6.7%, 6.7%, P >.05) and after 4 years (all 6.5%, P >.5). Hemoglobin A1c levels at initiation of the first (7.5%-7.6%) and second (8.0%-8.2%) oral medications for patients of nurse practitioners and physician assistants compared with that of physicians was also similar after adjusting for patient characteristics (all P >.05). Nurse practitioners started insulin at a lower hemoglobin A1c (9.4%) than physicians (9.7%), which remained significant after adjustment (P <.05). Conclusions: At diagnosis and during 4 years of follow-up, diabetes management by nurse practitioners and physician assistants was comparable to management by physicians. The Veterans Health Administration model for roles of nurse practitioners and physician assistants may be broadly useful to help meet the demand for primary care providers in the United States.

Copyright information:

© 2018

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote